|
Virtual Meetings 2021
Meet The Professor: Optimizing the Selection and Sequencing of Therapy for Patients with Triple-Negative Breast CancerFor more information, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153. PARTICIPATING FACULTY
Aditya Bardia, MD, MPH Director, Breast Cancer Research Program Associate Professor Harvard Medical School Attending Physician Massachusetts General Hospital Boston, Massachusetts Erika Hamilton, MD Director, Breast and Gynecologic Research Program Sarah Cannon Research Institute/Tennessee Oncology Nashville, Tennessee Sara Hurvitz, MD Professor of Medicine David Geffen School of Medicine at UCLA Director, Breast Cancer Clinical Research Program Co-Director, Santa Monica-UCLA Outpatient Oncology Practice Santa Monica, California Rita Nanda, MD Director, Breast Oncology Associate Professor of Medicine Section of Hematology/Oncology The University of Chicago Chicago, Illinois Joyce O’Shaughnessy, MD Celebrating Women Chair in Breast Cancer Research Baylor University Medical Center Director, Breast Cancer Research Program Texas Oncology US Oncology Dallas, Texas Professor Peter Schmid, FRCP, MD, PhD Centre Lead Centre for Experimental Cancer Medicine Barts Cancer Institute London, United Kingdom Charles L Vogel, MD Breast Medical Oncology Baptist Health South Florida Miami Cancer Institute Plantation, Florida Additional faculty to be announced. SERIES MODERATOR Neil Love, MD Research To Practice Agenda
Topics to Be Discussed
Target Audience
CME Credit Form American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Bardia — Consulting Agreements: AstraZeneca Pharmaceuticals LP, bioTheranostics Inc, Daiichi Sankyo Inc, Foundation Medicine, Genentech, a member of the Roche Group, Immunomedics Inc, Lilly, Merck, Novartis, Pfizer Inc, Phillips HealthCare Services Ltd, Puma Biotechnology Inc, Radius Health Inc, Sanofi Genzyme, Taiho Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Immunomedics Inc, Merck, Novartis, Pfizer Inc, Radius Health Inc, Sanofi Genzyme. Dr Hamilton — Advisory Committee and Consulting Agreements (No Personal Fees): Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Deciphera Pharmaceuticals Inc, Eisai Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Lilly, Merck, Mersana Therapeutics, Novartis, Pfizer Inc, Puma Biotechnology Inc, Seagen Inc, Silverback Therapeutics; Contracted Research (to Institution Only): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Akesobio Australia Pty Ltd, Amgen Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dana Farber Cancer Hospital, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, ImmunoGen Inc, Immunomedics Inc, Infinity Pharmaceuticals Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Merck, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, Olema Oncology, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Orinove Inc, Pfizer Inc, PharmaMar, Plexxikon Inc, Polyphor, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seagen Inc, Sermonix Pharmaceuticals, Shattuck Labs, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, Torque Therapeutics, Verastem Inc, Zenith Epigenetics, Zymeworks. Dr Hurvitz — Contracted Research: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, Dignitana AB, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Immunomedics Inc, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed LLC, Sanofi Genzyme, Seagen Inc, Zymeworks; Stock Investment: NKMax; Stock Investment (Spouse): Ideal Implant Incorporated, ROMTech. Dr Nanda — Advisory Committee: Cardinal Health, Clovis Oncology, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, iTeos Therapeutics, MacroGenics Inc, Merck, OncoSec Medical, Pfizer Inc, Seagen Inc; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Corcept Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, Immunomedics Inc, Merck, OBI Pharma Inc, Odonate Therapeutics, OncoSec Medical, Pfizer Inc, Seagen Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: G1 Therapeutics Inc. Dr O’Shaughnessy — Consulting Agreements: AbbVie Inc, Agendia Inc, Amgen Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, Halozyme Inc, Heron Therapeutics, Immunomedics Inc, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Myriad Genetic Laboratories Inc, Nektar, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Pierre Fabre, Puma Biotechnology Inc, Roche Laboratories Inc, Samsung Bioepis, Sanofi Genzyme, Seagen Inc, Syndax Pharmaceuticals Inc, Synthon, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Speakers Bureau: Lilly, Pfizer Inc, Seagen Inc. Prof Schmid — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, Merck, Novartis, Pfizer Inc, Puma Biotechnology Inc, Roche Laboratories Inc; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, Medivation Inc, a Pfizer Company, Novartis, OncoGenex Pharmaceuticals Inc, Roche Laboratories Inc; Spouse Employment/Salary: Roche Laboratories Inc. Dr Vogel — Advisory Board and Consulting Agreements: bioTheranostics Inc, Pfizer Inc, Puma Biotechnology Inc, Veru Inc.SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.Supporters These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc and Merck. |